Evidence map›Paper›PMID 22617158›Full record

ArticleBritish journal of cancer2012

Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort.

V A Grote, R Kaaks, A Nieters, A Tjønneland, J Halkjær, K Overvad, M R Skjelbo Nielsen, M C Boutron-Ruault, F Clavel-Chapelon, A Racine and 35 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Circulating Inflammation Markers and Pancreatic Cancer Risk: A Prospective Case-Cohort Study in Japan.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 11 countries.

V A GroteDivision of Cancer Epidemiology (c020), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg 69120, Germany.
R Kaaks
A Nieters
A Tjønneland
J Halkjær
K Overvad
M R Skjelbo Nielsen
M C Boutron-Ruault
F Clavel-Chapelon
A Racine
B Teucher
S Becker
T Pischon
H Boeing
A Trichopoulou
C Cassapa
V Stratigakou
D Palli
V Krogh
R Tumino
P Vineis
S Panico
L Rodríguez
E J Duell
M-J Sánchez
M Dorronsoro
C Navarro
A B Gurrea
P D Siersema
P H M Peeters
W Ye
M Sund
B Lindkvist
D Johansen
K-T Khaw
N Wareham
N E Allen
R C Travis
V Fedirko
M Jenab
D S Michaud
S-C Chuang
D Romaguera
H B Bueno-de-Mesquita
S Rohrmann
Heidelberg University · DEImperial College London · GBCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESUniversity Medical Center Utrecht · NLCentre International de Recherche sur le Cancer · FRDanish Cancer Society · DKHellenic Health Foundation · GRUniversity of Cambridge · GBUniversity of Oxford · GBAarhus University · DKAarhus University Hospital · DKAzienda Usl 8 Arezzo · ITCentre de recherche en Epidémiologie et Santé des Populations · FRFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DEInserm · FRInstitut Català d'Oncologia · ESInstitute of Social and Preventive Medicine · CHInstitut Gustave Roussy · FR

Funding

British Heart FoundationCancer Research UKDepartment of HealthMedical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_U106179471Wellcome Trust
6 · The paper itself

Abstract

backgroundEstablished risk factors for pancreatic cancer include smoking, long-standing diabetes, high body fatness, and chronic pancreatitis, all of which can be characterised by aspects of inflammatory processes. However, prospective studies investigating the relation between inflammatory markers and pancreatic cancer risk are scarce.

methodsWe conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition, measuring prediagnostic blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), and soluble receptors of tumour necrosis factor-α (sTNF-R1, R2) in 455 pancreatic cancer cases and 455 matched controls. Odds ratios (ORs) were estimated using conditional logistic regression models.

resultsNone of the inflammatory markers were significantly associated with risk of pancreatic cancer overall, although a borderline significant association was observed for higher circulating sTNF-R2 (crude OR=1.52 (95% confidence interval (CI) 0.97-2.39), highest vs lowest quartile). In women, however, higher sTNF-R1 levels were significantly associated with risk of pancreatic cancer (crude OR=1.97 (95% CI 1.02-3.79)). For sTNF-R2, risk associations seemed to be stronger for diabetic individuals and those with a higher BMI.

conclusionProspectively, CRP and IL-6 do not seem to have a role in our study with respect to risk of pancreatic cancer, whereas sTNF-R1 seemed to be a risk factor in women and sTNF-R2 might be a mediator in the risk relationship between overweight and diabetes with pancreatic cancer. Further large prospective studies are needed to clarify the role of proinflammatory proteins and cytokines in the pathogenesis of exocrine pancreatic cancer.

Indexed as

AdultAgedBiomarkers, TumorCase-Control StudiesCohort StudiesC-Reactive ProteinFemaleHumansInflammationInterleukin-6MaleMiddle AgedPancreatic NeoplasmsReceptors, Tumor Necrosis FactorRisk FactorsBiomarkers, TumorC-Reactive ProteinInterleukin-6Receptors, Tumor Necrosis Factor

Identifiers

PMID22617158
PMCPMC3364108
OpenAlexW2096319211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.